BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.
Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)
Nils Eckardt, Vice President Medical Affairs, Europe, shares BeiGene’s innovative vision for patients.
A short summary describing a next-generation BTK inhibitor with sustained and potent activity at disease sites and low off-target kinase inhibition.